Detalles de la búsqueda
1.
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 24(6): 646-657, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37182538
2.
Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study.
Int J Cancer
; 153(10): 1809-1818, 2023 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37543965
3.
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
Breast Cancer Res Treat
; 197(3): 489-501, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36459284
4.
Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial.
BMC Med
; 21(1): 300, 2023 08 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37559142
5.
Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial.
BMC Med
; 21(1): 226, 2023 06 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37365596
6.
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial.
Lancet Oncol
; 23(3): 353-361, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35085506
7.
A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
BMC Med
; 20(1): 321, 2022 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36184642
8.
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(3): 351-360, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33581774
9.
Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study.
Int J Cancer
; 148(3): 692-701, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32700765
10.
A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy.
Oncologist
; 26(5): e742-e748, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33245164
11.
Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy.
BMC Cancer
; 21(1): 341, 2021 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-33789616
12.
Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018).
Cancer
; 126 Suppl 16: 3867-3882, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32710660
13.
Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial.
Invest New Drugs
; 38(2): 507-514, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32036491
14.
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(6): 806-815, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31036468
15.
Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients.
J Transl Med
; 17(1): 27, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30646914
16.
Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
Oncologist
; 22(11): 1333-1338, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28798274
17.
Cytochrome P450 1A1 (CYP1A1) Gene Polymorphisms and Susceptibility to Breast Cancer: a Meta-Analysis in the Chinese Population.
Clin Lab
; 63(1): 67-72, 2017 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28164497
18.
Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.
Health Qual Life Outcomes
; 14: 51, 2016 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-27009092
19.
The Val158Met polymorphism in the COMT gene is associated with increased cancer risks in Chinese population.
Tumour Biol
; 35(4): 3003-8, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24307619
20.
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial.
Nat Commun
; 15(1): 1015, 2024 Feb 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38310192